A 204
Alternative Names: A-204Latest Information Update: 05 Mar 2024
Price :
$50 *
At a glance
- Originator Klus Pharma
- Class Antivirals
- Mechanism of Action Capsid protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Hepatitis B
Most Recent Events
- 23 Jan 2024 A 204 is available for licensing as of 23 Jan 2024. https://www.kluspharma.com/contact
- 22 Jan 2024 Phase-I clinical trials in Hepatitis B (In volunteers) (unspecified route) (Klus Pharma pipeline, January 2024)